Zegerid: adverse event reports filed with FDA

1,117

reports as suspect product

0% of all reports · about 53 a year

0

reports, 12 months to June 2026

2 in the 12 months before

88%

marked serious by the reporter

86.4% across the class

10%

record death among outcomes, as reported

112 reports · not verified by FDA

Reports by month, five years

Reports by the month FDA received them. FDA releases FAERS data quarterly, so the newest months are incomplete and grow in later releases.

By year received

Reactions recorded in the reports

share of Zegerid reports recording the termmedian drug in proton pump inhibitor

1. Chronic kidney diseaselong-term kidney disease71.4%798
2. Acute kidney injurysudden loss of kidney function40.2%449
3. Renal failurekidney failure37.7%421
4. End stage renal diseasekidney failure needing dialysis or transplant20.1%225
5. Renal injury18.9%211
6. Tubulointerstitial nephritis9.4%105
7. Gastrooesophageal reflux diseaseacid reflux8.6%96
8. Nephrogenic anaemia5.8%65
9. Rebound acid hypersecretion5.7%64
10. Renal impairmentreduced kidney function5.6%63
11. Nephropathy4.5%50
12. Deaththe patient died; cause not stated by this term3.4%38
13. Drug ineffectivethe medicine did not work as expected2.9%32
14. Hyperparathyroidism secondary2.9%32
15. Nephrolithiasiskidney stones2.2%25
16. Depressionlow mood2.1%24
17. Renal cyst2.1%24
18. Hypertensive nephropathy2.1%23
19. Renal disorder1.9%21
20. Dialysisdialysis1.8%20
21. Hypertensionhigh blood pressure1.6%18
22. Chronic kidney disease-mineral and bone disorder1.4%16
23. Haematuriablood in the urine1.4%16
24. Renal tubular necrosis1.3%15
25. Anxietyanxiety1.3%14
26. Nocturia1.3%14
27. Pollakiuriapassing urine more often1.3%14
28. Proteinuriaprotein in the urine1.3%14
29. Dizzinesslight-headedness or unsteadiness1.2%13
30. Hyperchlorhydria1.2%13

Top 30 of 227 MedDRA preferred terms recorded across these reports, with a plain-language gloss where one is available. One report can record several terms. The hollow bar is the median share across the 22 drugs in the proton pump inhibitor class; it describes the reports, not the patients. FDA states that adverse event reports "represent a small percentage of total usage numbers of a product", that "common products may have a higher number of adverse events due to the higher total number of people using the product", and that the data "by themselves are not an indicator of the safety profile of the drug or biologic."

Outcomes recorded

Outcome flags as the reporter set them; a report can carry several, and "other serious" is FDA's own category for serious reports outside the named outcomes. Grey bar: all 484,090 reports in the class. FDA has not verified any outcome and states that the reports "cannot be used to estimate the incidence of these events."

Patients and reporters

Age and sex as stated in the report; the reporter's qualification is the primary source recorded by FDA. 99.3% of reports give the United States as the country of the event or reporter.

Reason for use recorded

The indication field is filled in by the reporter and is often blank; shares are of all 1,117 reports.

Drugs most often listed in the same reports

Other products listed in reports where Zegerid is a suspect product, whatever their own role. Co-listing means the two were recorded together; it says nothing about either product's part in the event. Only the 2,500 most-reported names are counted here.

In context

Shares are of reports, not of patients treated. The number of people taking a product is not in the data, so none of these figures is a rate, and differences between columns reflect who takes a product, who reports and how long it has been sold. FDA states that adverse event reports "represent a small percentage of total usage numbers of a product", that "common products may have a higher number of adverse events due to the higher total number of people using the product", and that the data "by themselves are not an indicator of the safety profile of the drug or biologic."

Other drugs in the proton pump inhibitor class

Ordered by report count for navigation only. FDA states that adverse event reports "represent a small percentage of total usage numbers of a product", that "common products may have a higher number of adverse events due to the higher total number of people using the product", and that the data "by themselves are not an indicator of the safety profile of the drug or biologic." A brand and its generic are separate rows because reporters name them separately.

Where this comes from. Counts are built from the openFDA Drug Adverse Event (FAERS) bulk export released 28 Sep 2026, which holds reports FDA received through 30 Jun 2026. Drug names are as reported, resolved to the brand or generic name on the FDA label where openFDA's harmonisation matched them; classes are the pharmacologic class (EPC) from the label and the National Drug Code Directory of 17 Sep 2026. A report counts here when it lists Zegerid as a suspect or interacting product; reports listing it only as a concomitant medication (1,335) are excluded. No report narrative, lot number, patient detail or reporter identity is published. See the methodology and sources; FDA's record is authoritative, and corrections are handled within five working days.